sever
acut
respiratori
syndrom
coronaviru
sarscov
still
carri
potenti
reemerg
therefor
effort
made
creat
vaccin
prophylact
strategi
control
prevent
antibodydepend
enhanc
ade
mechan
dengu
virus
felin
coronavirus
hiv
virus
take
advantag
antivir
humor
immun
respons
infect
host
target
cell
describ
observ
sarscov
use
ade
enhanc
infect
hlcz
human
promonocyt
cell
line
quantitativepcr
immunofluoresc
stain
result
indic
sarscov
capabl
replic
hlcz
cell
display
virusinduc
cytopath
effect
increas
level
tnfa
two
day
postinfect
accord
flow
cytometri
data
hlcz
cell
also
express
angiotensin
convert
enzym
sarscov
receptor
higher
level
fccrii
receptor
found
higher
concentr
antisera
sarscov
neutral
sarscov
infect
highli
dilut
antisera
significantli
increas
sarscov
infect
induc
higher
level
apoptosi
result
infect
assay
indic
sarscov
ade
primarili
mediat
dilut
antibodi
envelop
spike
protein
rather
nucleocapsid
protein
also
gener
monoclon
antibodi
sarscov
spike
protein
observ
promot
sarscov
infect
combin
result
suggest
antibodi
sarscov
spike
protein
may
trigger
ade
effect
data
rais
new
question
regard
potenti
sarscov
vaccin
shed
light
mechan
involv
sar
pathogenesi
coronavirus
envelop
virus
posit
strand
cap
polyadenyl
rna
genom
rang
kb
coronavirus
caus
respiratori
enter
diseas
human
domest
animalsfor
exampl
human
coronavirus
known
caus
mild
upper
respiratori
tract
infect
new
sever
acut
respiratori
syndrom
coronaviru
sarscov
discov
outbreak
diseas
infect
individu
kill
identifi
case
occur
asia
origin
assum
sarscov
transmit
via
respiratori
droplet
direct
contact
howev
research
suggest
also
spread
via
airborn
unknown
process
sarscov
genom
consist
put
open
read
frame
orf
mrna
transcript
account
approxim
twothird
genom
encod
larg
polyprotein
genom
encod
four
major
structur
protein
spike
envelop
e
membran
nucleocapsid
n
viral
surfac
spike
glycoprotein
initi
sarscov
entri
cell
bind
angiotensinconvert
enzym
receptor
follow
conform
chang
result
membran
fusion
genom
deliveri
cytoplasm
sarscov
protein
type
transmembran
protein
consist
distinct
ntermin
ctermin
domain
respect
mediat
receptor
bind
viruscel
fusion
protein
key
target
gener
protect
neutral
antibodi
coronavirus
minor
alter
protein
affect
tissu
speci
tropism
coronaviru
virul
primari
function
nucleocapsid
protein
form
helic
ribonucleoprotein
complex
viral
rna
vrna
addit
compris
core
structur
sarscov
virion
complex
involv
multipl
function
transcript
replic
viru
packag
sever
vaccin
strategi
studi
target
sarscov
spike
gene
protein
induc
neutral
protect
antibodi
howev
signific
concern
vaccin
differ
kind
coronavirus
markedli
differ
outcom
exampl
antispik
antibodi
offer
protect
mous
hepat
transmiss
gastroenter
boost
felinecoronaviru
fcov
infect
altern
viru
entri
process
known
antibodi
depend
enhanc
ade
observ
virus
dengu
yellow
fever
hiv
fcov
among
other
although
ade
mechan
complet
understood
gener
assum
increas
viru
yield
due
infect
larg
number
suscept
cell
increas
mediat
immunoglobulin
receptor
fc
fcr
complement
receptor
facilit
uptak
virusantibodi
complex
phagocyt
result
enhanc
target
cell
infect
howev
remain
unclear
whether
sarscov
use
ade
enhanc
infect
use
sarscov
clinic
isol
pseudotyp
virus
determin
whether
ade
occur
sarscov
infect
experi
involv
human
promonocyt
cell
line
hlcz
yet
report
sarscov
infect
accord
data
hlcz
cell
express
fcrii
receptor
infect
sarscov
also
note
dilut
antisera
sarscov
promot
sarscov
infect
phenomenon
significantli
mediat
anti
antibodi
final
one
sever
monoclon
antibodi
protein
gener
project
express
neutral
action
other
display
mildtomoder
ade
effect
hlcz
cell
approv
obtain
sera
sarscov
patient
appli
receiv
institut
ethic
committe
nation
yangm
univers
procedur
conduct
accord
committe
rule
five
cell
line
use
hlcz
human
promonocyt
isol
leukemia
patient
human
kidney
african
green
monkey
kidney
raji
b
monocyt
sarscov
strain
genbank
access
obtain
taiwan
center
diseas
control
taiwan
cdc
sarscov
pseudotyp
viru
particl
carri
sarscov
protein
gener
cotransfect
cell
pnllucerand
antisar
cov
sera
collect
sarscovinfect
patient
confirm
taiwan
cdc
lab
hlcz
cell
well
use
direct
infect
assay
sarscov
pseudotyp
virus
moi
incub
cell
h
serumfre
medium
wash
pb
follow
incub
ml
rpmi
dmem
medium
contain
serum
iu
penicillin
lgml
streptomycin
antibiot
ad
follow
anoth
incub
co
differ
length
time
viral
supernat
infect
cell
lysat
collect
subject
quantit
rtpcr
analys
aim
orfib
region
pseudotyp
sarscov
particl
quantiti
determin
term
luciferas
activ
neutral
assay
hlcz
vero
cell
ad
tissu
cultur
plate
cellswel
sarscov
tcid
sarscov
pseudotyp
virus
ng
mix
variou
mab
sera
differ
dilut
incub
h
ad
hlcz
vero
cell
cultur
supernat
collect
postinfect
viral
load
measur
realtim
rtpcr
viral
rna
extract
cultur
supernat
use
qiaamp
viral
rna
mini
kit
qiagen
two
realtim
rtpcr
primer
set
use
measur
mrna
forward
revers
nucleocapsid
us
cdc
catalogu
bniout
bniouta
orf
ib
cell
harvest
held
min
pb
contain
fb
follow
anoth
min
incub
isotypematch
control
monoclon
antibodi
lgml
indic
human
fc
receptor
immunofluoresc
stain
procedur
describ
taiwanes
sarscov
isol
strain
genbank
access
use
templat
clone
amplifi
nucleocapsid
spike
gene
use
plasmid
express
prokaryot
system
detail
scheme
describ
supplement
file
see
especi
sfig
procedur
gener
monoclon
polyclon
antibodi
describ
briefli
balbc
mice
immun
given
two
booster
lg
gstspike
gstsia
sib
sii
recombin
protein
ml
pb
emulsifi
equal
volum
completeincomplet
freund
adjuv
sigmaaldrich
st
loui
mo
elisa
western
blot
use
confirm
antibodi
titer
recombin
fusion
protein
prior
harvest
splenocyt
fuse
myeloma
cell
elisa
western
blot
also
use
screen
hybridoma
cultur
supernat
gstspike
fusion
protein
clone
produc
specif
antibodi
select
use
dilut
method
describ
hlcz
cell
apoptosi
assay
perform
use
annexin
v
stain
hlcz
cell
infect
sarscov
incub
h
cultur
supernat
concentr
ultracentrifug
rpm
h
lyse
sdspage
sampl
buffer
sdspage
electrophoresi
perform
accord
protocol
given
assay
detail
previous
describ
assay
perform
use
sera
normal
sarscovposit
patient
rabbit
polyclon
mous
monoclon
antibodi
n
protein
use
evalu
ade
hlcz
cell
infect
sarscov
pseudotyp
virus
presenc
control
either
antispik
antinucleocapsid
antibodi
dilut
incub
h
supernat
cell
lysat
collect
viral
titer
determin
quantit
rtpcr
luminesc
analys
experi
perform
minimum
three
time
graphpad
prism
softwar
use
statist
analys
statist
signific
p
calcul
use
unpair
student
ttest
previou
research
infect
hlcz
human
promonocyt
cell
dengu
virus
among
sever
other
infect
assay
result
indic
hlcz
infect
sarscov
fig
accord
quantit
rtpcr
data
higher
mrna
express
level
tnfa
detect
hlcz
cell
postinfect
fig
trace
level
also
detect
data
shown
light
microscopi
immunofluoresc
stain
observ
indic
cytopath
effect
cpe
postinfect
fig
b
presenc
sarscov
sarscovinfect
hlcz
cell
detect
antisera
collect
sarscovposit
patient
fig
infecti
sarscov
viru
product
hlcz
cell
confirm
use
supernat
cell
infect
cell
known
suscept
coronavirus
also
observ
signific
cpe
cell
day
postinfect
fig
hlcz
cell
express
angiotensinconvert
enzym
ace
fcc
receptor
display
antibodydepend
sarscov
infect
function
sarscov
receptor
abund
human
lung
small
intestin
epitheli
cell
fc
receptor
fcr
complement
receptor
identifi
altern
cellular
entri
certain
virus
shown
enhanc
antibodydepend
infect
flow
cytometri
result
indic
hlcz
cell
express
receptor
higher
level
fcrii
fig
tri
determin
antibodydepend
enhanc
also
occur
sarscovinfect
hlcz
cell
data
indic
treatment
antisera
collect
sarscov
patient
dilut
result
increas
viru
infect
cpe
compar
treatment
dilut
antisera
fig
accord
transmiss
electron
microscopi
imag
higher
quantiti
sarscov
viral
particl
observ
hlcz
cell
treat
dilut
antisera
sarscov
dilut
fig
compar
treat
less
dilut
antisera
fig
less
dilut
normal
control
sera
fig
perform
addit
infect
assay
confirm
observ
found
significantli
higher
level
viru
infect
follow
treatment
dilut
antisera
compar
control
sera
nonsarscov
patient
dilut
p
fig
also
found
highli
dilut
antisera
sarscov
significantli
increas
virusinduc
apoptosi
hlcz
cell
compar
normal
sera
dilut
p
fig
next
task
determin
antibodi
promot
sarscov
infect
note
antibodi
n
protein
produc
high
level
sarscov
infect
therefor
use
sand
nproteinrecogn
antibodi
detect
earli
sarscov
infect
gener
mous
antibodi
n
recombin
protein
supplement
fig
perform
infect
assay
use
differ
mous
sera
n
protein
differ
dilut
assay
result
indic
dilut
anti
mous
sera
exhibit
significantli
greater
sarscov
ade
effect
hlcz
cell
compar
dilut
mous
control
sera
p
fig
note
dilut
antin
mous
sera
exert
sarscov
ade
effect
hlcz
cell
fig
seri
monoclon
antibodi
mab
spike
protein
gener
confirm
find
supplement
fig
sprotein
epitop
recogn
mab
shown
fig
shown
epitop
nynwkr
sib
region
neutral
capabl
monoclon
antibodi
protein
exhibit
mildtomoder
enhanc
effect
lentivir
particl
carri
luciferas
gene
pseudotyp
sar
envelop
spike
protein
fig
infect
assay
result
also
indic
mab
significantli
inhibit
sarscov
infect
hlcz
cell
promot
viru
infect
compar
isotyp
control
accord
microscopi
observ
promot
significantli
stronger
cpe
compar
also
display
neutral
capabl
isotyp
control
fig
gener
protect
antibodi
specif
protein
use
strategi
microbi
diseas
control
immun
respons
pathogen
deleteri
effectsfor
exampl
cytokin
storm
associ
avian
influenza
viru
increas
mortal
sarscov
infect
cell
infect
via
antibodydepend
enhanc
observ
sever
viral
diseas
includ
dengu
viru
felin
infecti
periton
viru
fipv
present
studi
identifi
suscept
altern
cell
line
hlcz
sarscov
infect
fig
specif
found
hlcz
cell
express
receptor
display
cytopath
effect
induc
sarscov
two
research
team
report
serv
function
receptor
sarscov
infect
human
peripher
monocyt
macrophag
infect
sarscov
result
suggest
hlcz
serv
altern
cell
line
sarscov
researchspecif
sarscovinfect
hlcz
cell
show
increas
tnfa
secret
fig
trace
amount
accord
two
studi
human
peripher
monocyt
macrophag
infect
sarscov
anoth
research
group
observ
upregul
tnfa
induc
sarscov
spike
protein
murin
macrophag
identifi
key
sarscovinduc
epitheli
cytokin
combin
data
suggest
sarscovinduc
tnfa
play
role
sar
pathogenesi
especi
term
inflamm
high
fever
current
licens
vaccin
human
coronavirus
anim
vaccin
gener
sever
includ
transmiss
gastroenter
viru
howev
attempt
develop
felin
coronaviru
vaccin
fail
due
ade
mediat
receptorsmost
notabl
fc
gamma
receptor
fccr
facilit
antigenantibodi
complex
uptak
target
cell
data
indic
hlcz
cell
express
high
level
fccrii
accord
one
report
fccrii
play
predomin
role
mediat
sarscov
use
antibodi
differ
type
fccr
immun
cell
studi
raji
daudi
cell
display
ade
sarscov
infect
found
fcyrii
receptor
express
raji
hlcz
cell
supplement
fig
combin
find
suggest
fcyrii
import
ade
mediat
type
immun
cell
sarscov
infect
antibodi
capabl
increas
viru
replic
effici
either
boost
uptak
infecti
antibodyviru
complex
increas
synthesi
viral
protein
nucleic
acid
least
one
report
indic
compar
untreat
virus
replic
speed
virus
pretreat
antibodi
accord
anoth
report
higher
fipv
infect
rate
macrophag
occur
antifipv
antibodi
present
found
higher
concentr
antisera
collect
sarscovinfect
patient
dilut
display
greater
viral
neutral
capabl
compar
dilut
concentr
facilit
sarscov
infect
induc
higher
level
virusinduc
apoptosi
fig
found
phenomenon
occur
via
ade
mediat
anti
antibodi
antin
antibodi
least
two
studi
shown
sarscov
infect
induc
abund
amount
antibodi
n
protein
spike
protein
especi
bind
region
aa
capabl
produc
sarscovneutr
antibodi
nucleocapsid
protein
induc
cytotox
lymphocyt
ctl
immun
respons
specif
sarscovprotect
howev
anoth
research
team
suggest
sarscov
subunit
vaccin
may
induc
neutral
andor
partial
ade
effect
via
b
lineag
cell
separ
report
describ
similar
result
research
suggest
vaccineinduc
antispik
antibodi
trimer
protein
may
mediat
ade
sarscovpseudotyp
viru
entri
fcrexpress
cell
antispik
monoclon
antibodi
data
indic
sia
region
aa
display
ade
effect
sarscovpseudotyp
fig
real
virus
fig
one
monoclon
antibodi
slb
region
aa
show
viral
neutral
capabl
associ
mechan
requir
investig
studi
identifi
altern
suscept
cell
line
hlcz
futur
sarscov
research
found
ade
associ
sarscov
infect
primarili
mediat
antispik
antibodi
hope
inform
use
develop
human
sarscov
vaccin
well
research
involv
immunemedi
infect
tie
sar
pathogenesi
